Kodak invented the digital camera but shelved it to protect film sales. Similarly, search engine Excite passed on buying Google for $750k because better results reduced ad-serving time. Both prioritized current revenue over disruptive innovation, leading to their demise.

Polaroid founder Edwin Land, Steve Jobs's hero, operated on a simple but profound motto: avoid doing anything that could be done by someone else. This forces radical differentiation and is a powerful filter for creating truly unique work.

Before becoming a biotech hub, Kendall Square's technological and infrastructure foundation was laid by non-biotech companies like Polaroid. This pre-existing industrial base, including old factories and a skilled workforce, provided the initial ingredients that allowed early biotech giants like Genzyme to establish themselves and thrive.

A promising drug can be rendered obsolete if a competitor develops a superior, disease-modifying therapy that eliminates the original market need. This highlights that competitive dynamics are as critical as scientific validity, as when a cystic fibrosis therapy was sidelined by Vertex's core treatment.

The CEO believes the most profound lessons in biotech come from speaking with founders of companies that did not succeed. In an industry defined by high clinical trial risk, understanding the missteps and navigating the challenges of unsuccessful ventures provides more practical wisdom than studying success stories alone.

This quote urges companies to embrace continuous innovation and self-disruption. Instead of protecting a cash cow, leaders should actively seek the next breakthrough that will replace it. This mindset is crucial for long-term survival in a changing market, as customer needs and technologies inevitably evolve.

The biotech industry is uniquely conservative, with a culture where even the smartest minds are beholden to established processes. This resistance to questioning norms, like automatically running two Phase 3 trials, stifles innovation and slows progress compared to other technology sectors.

The pharmaceutical industry risks repeating Kodak's failure of inventing but ignoring a disruptive technology. For Kodak, it was digital photography; for pharma, it's AI. The industry possesses vast amounts of data (the new 'film'), but the real danger lies in failing to embrace the AI-driven intelligence layer that can interpret and act on it.

Like Kodak and Blockbuster, businesses fail by clinging to a model that works, right up until it's made obsolete by disruption. In the AI age, you must be willing to perform 'creative destruction' on your own successful systems before the market does it for you.